I believe that the recent failure of Fulcrum Therapeutics' key trial for losmapimod and the focus on alternative programs indicate potential instability ahead. As a result, I am taking a short position, anticipating further declines in the stock as the market reacts to these developments.

Given Ubisoft's significant share price surge following Jefferies' double upgrade and a positive outlook on its monetization strategy, I believe that UBSFY is currently overvalued and poised for a correction. Thus, I consider it a prime candidate for a short position.

I decided to invest in TER due to Goldman Sachs upgrading the stock to a Buy with a raised price target, and despite short-term bearish market sentiment, the overall bullish view from analysts suggests potential for upward movement in the near future.